Stocks · News reference
Alumis shares are trading lower after the company announced its Phase 2b LUMUS trial of envudeucitinib did not meet its primary and secondary endpoints in the overall trial population.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $37
Read original at benzingaWells Fargo Maintains Overweight on Alumis, Lowers Price Target to $25
Read original at benzingaSirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
Read original at benzinga